Six months after the UK Health and Social Care Act came into force disrupting commissioning and putting in place new outcome targets for the health system, pharmaceutical companies are looking carefully at what this means for their products. Across Europe, the need to demonstrate value to multiple stakeholders, each with their own priorities, has created a complex environment in which there is no single definition of value that will resonate.

“Getting UK Market Access Right: the Importance of a Local Value Story in the New NHS”, outlines how companies can maximize their probability of success amidst new regulatory and reimbursement realities. It highlights the need for pre-launch market access activity up to two years prior to launch in order to understand the system in which the product may be used, and what outcome data should be collected in support of the product’s value proposition.